The Global Pharmacogenomics Market was valued at USD 6.6 billion in 2024 and is estimated to grow at a CAGR of 10.4% to reach USD 17.7 billion by 2034.
The steady growth is fueled by increasing demand for targeted therapies and the ongoing development of genomic technologies. As healthcare systems worldwide push for more personalized treatment approaches, pharmacogenomic testing is seeing wider adoption across clinical and research settings. The expanding role of genomics in decision-making is further propelled by the burden of chronic diseases such as cancer, cardiovascular diseases, and infectious conditions. Pharmacogenomics focuses on understanding how a person’s genetic code influences their drug response, allowing clinicians to fine-tune dosages and treatment options for improved safety and efficacy. The ongoing shift toward digital health solutions, combined with the integration of AI-powered clinical decision tools and real-world data analytics, continues to advance the field. The market’s progress is directly tied to the broader move toward personalized medicine and the need to reduce adverse drug reactions while enhancing therapeutic outcomes.
In 2024, the products segment held a 67.1% share, driven by rising demand for tools supporting personalized care. This category includes instruments, consumables, and a wide range of genetic testing kits and reagents, which are essential for clinical and research use. Subsegments such as sequencing kits, PCR-based reagents, microarrays, and other diagnostic tools are widely used across various specialties, including cardiology, oncology, psychiatry, and infectious diseases. The increasing need for precision-driven solutions in therapeutic decision-making continues to boost demand for pharmacogenomic product offerings.
The personalized medicine segment generated USD 2.6 billion in 2024. Its rapid growth is attributed to the expansion of access to advanced genomic tools, improved diagnostics, and the integration of data analytics into routine care. Programs focused on national genomics initiatives are encouraging the inclusion of pharmacogenomic data into everyday clinical practice. Regulatory bodies are supporting this transition by approving relevant biomarkers that enable safer drug use and individualized therapy. Growing use of companion diagnostics and AI-powered technologies has made personalized medicine more scalable and widely accepted.
North America Pharmacogenomics Market held a 48.6% share in 2024. Market expansion in the U.S. and Canada is supported by a strong focus on genomic innovation, high healthcare expenditure, and advanced digital infrastructure. The increased adoption of genomic testing and personalized treatments across hospitals and clinics has been backed by favorable reimbursement policies, contributing to the widespread implementation of pharmacogenomic panels into clinical practice. Ongoing advancements in sequencing tools and AI-enabled diagnostics are enhancing clinical outcomes and driving regional market penetration.
Leading players in the Pharmacogenomics Market are expanding their market presence through strategic R&D investments, partnerships, and product diversification. Companies such as Thermo Fisher Scientific, Agilent Technologies, Illumina, and Qiagen are focused on developing comprehensive kits, reagents, and sequencing platforms that enable faster and more accurate genetic profiling. Collaborations with healthcare providers and research institutions help these firms co-develop custom solutions tailored to clinical needs. Mergers and acquisitions are being pursued to strengthen technological capabilities and widen geographic reach. Additionally, players are emphasizing regulatory approvals and compliance to ensure clinical relevance and market access.
This product will be delivered within 2-4 business days.
The steady growth is fueled by increasing demand for targeted therapies and the ongoing development of genomic technologies. As healthcare systems worldwide push for more personalized treatment approaches, pharmacogenomic testing is seeing wider adoption across clinical and research settings. The expanding role of genomics in decision-making is further propelled by the burden of chronic diseases such as cancer, cardiovascular diseases, and infectious conditions. Pharmacogenomics focuses on understanding how a person’s genetic code influences their drug response, allowing clinicians to fine-tune dosages and treatment options for improved safety and efficacy. The ongoing shift toward digital health solutions, combined with the integration of AI-powered clinical decision tools and real-world data analytics, continues to advance the field. The market’s progress is directly tied to the broader move toward personalized medicine and the need to reduce adverse drug reactions while enhancing therapeutic outcomes.
In 2024, the products segment held a 67.1% share, driven by rising demand for tools supporting personalized care. This category includes instruments, consumables, and a wide range of genetic testing kits and reagents, which are essential for clinical and research use. Subsegments such as sequencing kits, PCR-based reagents, microarrays, and other diagnostic tools are widely used across various specialties, including cardiology, oncology, psychiatry, and infectious diseases. The increasing need for precision-driven solutions in therapeutic decision-making continues to boost demand for pharmacogenomic product offerings.
The personalized medicine segment generated USD 2.6 billion in 2024. Its rapid growth is attributed to the expansion of access to advanced genomic tools, improved diagnostics, and the integration of data analytics into routine care. Programs focused on national genomics initiatives are encouraging the inclusion of pharmacogenomic data into everyday clinical practice. Regulatory bodies are supporting this transition by approving relevant biomarkers that enable safer drug use and individualized therapy. Growing use of companion diagnostics and AI-powered technologies has made personalized medicine more scalable and widely accepted.
North America Pharmacogenomics Market held a 48.6% share in 2024. Market expansion in the U.S. and Canada is supported by a strong focus on genomic innovation, high healthcare expenditure, and advanced digital infrastructure. The increased adoption of genomic testing and personalized treatments across hospitals and clinics has been backed by favorable reimbursement policies, contributing to the widespread implementation of pharmacogenomic panels into clinical practice. Ongoing advancements in sequencing tools and AI-enabled diagnostics are enhancing clinical outcomes and driving regional market penetration.
Leading players in the Pharmacogenomics Market are expanding their market presence through strategic R&D investments, partnerships, and product diversification. Companies such as Thermo Fisher Scientific, Agilent Technologies, Illumina, and Qiagen are focused on developing comprehensive kits, reagents, and sequencing platforms that enable faster and more accurate genetic profiling. Collaborations with healthcare providers and research institutions help these firms co-develop custom solutions tailored to clinical needs. Mergers and acquisitions are being pursued to strengthen technological capabilities and widen geographic reach. Additionally, players are emphasizing regulatory approvals and compliance to ensure clinical relevance and market access.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Offerings, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Disease Area, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
The companies profiled in this Pharmacogenomics market report include:- 23andMe
- Admera Health
- Agilent Technologies
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- Charles River Laboratories
- Danaher
- Eurofins Scientific
- F. Hoffmann-La Roche
- Genelex
- Genomind
- Illumina
- Laboratory Corporation of America Holdings
- Novogene
- OneOme
- Qiagen
- Revvity
- Takara Bio
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | October 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 6.6 Billion |
| Forecasted Market Value ( USD | $ 17.7 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
